Search research articles
Contact Us
Filters
Showing results (351-360 of 436) with videos related to
Page
of 44
Sort By:
Haematologica
|
April 15, 2021
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome
Mahesh Swaminathan, Hagop M Kantarjian, Mark Levis, et al.
Blood Cancer Journal
|
March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations
Warren Fiskus, Christopher P Mill, Jessica Piel, et al.
The Lancet. Haematology
|
March 7, 2024
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, et al.
American Journal of Hematology
|
August 28, 2023
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia
Tapan M Kadia, Farhad Ravandi, Matteo Molica, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia
Daniel Nguyen, Hagop M Kantarjian, Aram Bidikian, et al.
Cancer
|
October 29, 2020
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations
Mahran Shoukier, Tapan Kadia, Marina Konopleva, et al.
Leukemia & Lymphoma
|
October 20, 2021
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy
Jorge M Ramos Perez, Keyur P Patel, Sanam Loghavi, et al.
Oncotarget
|
March 9, 2018
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
Guillermo Montalban-Bravo, Koichi Takahashi, Keyur Patel, et al.
American Journal of Hematology
|
June 19, 2023
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation
Alexandre Bazinet, Hagop Kantarjian, Naszrin Arani, et al.
American Journal of Hematology
|
April 3, 2021
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS)
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Faezeh Darbaniyan, et al.
Page
of 44
Search research articles
Search
Showing results (351-360 of 436) with videos related to
Sort By:
Page
of 44
Haematologica
|
April 15, 2021
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome
Mahesh Swaminathan, Hagop M Kantarjian, Mark Levis, et al.
Blood Cancer Journal
|
March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations
Warren Fiskus, Christopher P Mill, Jessica Piel, et al.
The Lancet. Haematology
|
March 7, 2024
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, et al.
American Journal of Hematology
|
August 28, 2023
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia
Tapan M Kadia, Farhad Ravandi, Matteo Molica, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia
Daniel Nguyen, Hagop M Kantarjian, Aram Bidikian, et al.
Cancer
|
October 29, 2020
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations
Mahran Shoukier, Tapan Kadia, Marina Konopleva, et al.
Leukemia & Lymphoma
|
October 20, 2021
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy
Jorge M Ramos Perez, Keyur P Patel, Sanam Loghavi, et al.
Oncotarget
|
March 9, 2018
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
Guillermo Montalban-Bravo, Koichi Takahashi, Keyur Patel, et al.
American Journal of Hematology
|
June 19, 2023
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation
Alexandre Bazinet, Hagop Kantarjian, Naszrin Arani, et al.
American Journal of Hematology
|
April 3, 2021
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS)
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Faezeh Darbaniyan, et al.
Page
of 44